CD8A and lung carcinoma: It is instructive to consider CD8+ T cell responsiveness to current clinical immunotherapy along with the challenge of unique lung cancer mutations that both guides targeted and first-line therapy while significantly modifying CTL responsiveness and ultimate prognosis.